No back-peddling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977)
In Azurity v. Alkem the US Court of Appeals for the Federal Circuit (CAFC) affirmed the District of Delaware's ruling that Alkem's...
In Azurity v. Alkem the US Court of Appeals for the Federal Circuit (CAFC) affirmed the District of Delaware's ruling that Alkem's...
The decision of the Munich Local Division of the UPC in SES vs. Hanshow provides a first indication of how the nascent UPC will...
In the US, the principle of file wrapper estoppel is well established. Submissions made in US patent prosecution may be highly...
Following the high profile hearing last month, we are now all waiting with bated breath for the written decision of the Enlarged Board of...
The EPO Board of Appeal decision in T 0687/22 confirms beyond doubt the relevance of G 2/21 to software inventions. The decision in ...
The recent decision T 1913/21 highlights a crucial differentiation between second non-medical use claims and process claims. The Board...
The decision in T 0660/22 combines two hot topics, AI and cells! The patent application at issue related to a method for analysing...
The recent Board of Appeal decision in T 1977/22 related to the patentability of claims defining subject matter with open-ended...
The recent decision in Abbott v Sibio Technology ( UPC_CoA_382/2024 ) offers valuable insights into the UPC's approach to the...
Cell therapies represent incredibly exciting science and the opportunity to treat previously intractable diseases. Cell therapies...
Cell therapy represents one of the most exciting fields of innovation, with the potential to provide long-term cures for previously...
AlphaFold, a machine learning model for predicting protein structure, is arguably one of the greatest achievements of AI so far. Whilst...
In the US, functional antibody claims have increasingly failed to satisfy the strict "written description" sufficiency requirement. The...
The Board of Appeal decision in T 2130/22 considered the inventive step of a pharmaceutical formulation in which the technical effect...
OpenAI's approach to IP is often cited in the tech industry as an example of a radically new approach to IP. OpenAI has the reputation...